By studying tumor-immune dynamics through simulations, we found better-performing NK cell products possessing superior cellular properties including higher viability, cytotoxicity, and serial killing capacity, i.e. CD19IL15 CAR-NKs in treating lymphoma and IL21 NKs in treating GBM. The gene discussed is IL21; the disease is neoplasm.